Literature DB >> 15223147

Evidence that catalytically-inactivated thrombin forms non-covalently linked dimers that bridge between fibrin/fibrinogen fibers and enhance fibrin polymerization.

M W Mosesson1, I Hernandez, K R Siebenlist.   

Abstract

Phe-pro-arg-chloromethyl ketone-inhibited alpha-thrombin [FPR alpha-thr] retains its fibrinogen recognition site (exosite 1), augments fibrin/fibrinogen [fibrin(ogen)] polymerization, and increases the incorporation of fibrin into clots. There are two 'low-affinity' thrombin-binding sites in each central E domain of fibrin, plus a non-substrate 'high affinity' gamma' chain thrombin-binding site on heterodimeric 'fibrin(ogen) 2' molecules (gamma(A), gamma'). 'Fibrin(ogen) 1' (gamma(A), gamma(A)) containing only low-affinity thrombin-binding sites, showed concentration-dependent FPR alpha-thr enhancement of polymerization, thus indicating that low-affinity sites are sufficient for enhancing polymerization. FPR gamma-thr, whose exosite 1 is non-functional, did not enhance polymerization of either fibrin(ogen)s 1 or 2 and DNA aptamer HD-1, which binds specifically to exosite 1, blocked FPR alpha-thr enhanced polymerization of both types of fibrin(ogen) (1>2). These results showed that exosite 1 is the critical element in thrombin that mediates enhanced fibrin polymerization. Des B beta 1-42 fibrin(ogen) 1, containing defective 'low-affinity' binding sites, was subdued in its FPR alpha-thr-mediated reactivity, whereas des B beta 1-42 fibrin(ogen) 2 (gamma(A), gamma') was more reactive. Thus, the gamma' chain thrombin-binding site contributes to enhanced FPR alpha-thr mediated polymerization and acts through a site on thrombin that is different from exosite 1, possibly exosite 2. Overall, the results suggest that during fibrin clot formation, catalytically-inactivated FPR alpha-thr molecules form non-covalently linked thrombin dimers, which serve to enhance fibrin polymerization by bridging between fibrin(ogen) molecules, mainly through their low affinity sites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223147     DOI: 10.1016/j.bpc.2004.01.007

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  5 in total

1.  Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains.

Authors:  Kevin R Siebenlist; Michael W Mosesson; Irene Hernandez; Leslie A Bush; Enrico Di Cera; John R Shainoff; James P Di Orio; Laurie Stojanovic
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

2.  Cl- and F- anions regulate the architecture of protofibrils in fibrin gel.

Authors:  M Missori; M Papi; G Maulucci; G Arcovito; G Boumis; A Bellelli; G Amiconi; M De Spirito
Journal:  Eur Biophys J       Date:  2009-06-11       Impact factor: 1.733

3.  Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.

Authors:  Arne Lauer; Flor A Cianchetti; Elizabeth M Van Cott; Frieder Schlunk; Elena Schulz; Waltraud Pfeilschifter; Helmuth Steinmetz; Chris B Schaffer; Eng H Lo; Christian Foerch
Journal:  Circulation       Date:  2011-09-12       Impact factor: 29.690

4.  Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography.

Authors:  Sae-Yeon Won; Frieder Schlunk; Julien Dinkel; Hulya Karatas; Wendy Leung; Kazuhide Hayakawa; Arne Lauer; Helmuth Steinmetz; Eng H Lo; Christian Foerch; Rajiv Gupta
Journal:  Stroke       Date:  2013-08-06       Impact factor: 7.914

5.  No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.

Authors:  Ferdinand Bohmann; Ana Mirceska; Josef Pfeilschifter; Edelgard Lindhoff-Last; Helmuth Steinmetz; Christian Foerch; Waltraud Pfeilschifter
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.